Study of LW402 Tablets in Moderate to Severe Rheumatoid Arthritis
Status:
COMPLETED
Trial end date:
2024-08-30
Target enrollment:
Participant gender:
Summary
This Phase IIa study is designed to evaluate the dose-response relationship, efficacy, safety, and tolerability of LW402 tablets administered for 12 weeks in adult patients with active rheumatoid arthritis receiving background methotrexate (MTX) therapy.